Low molecular weight heparin (LMWH) is a kind of high efficiency and relatively safety sugar anticoagulants. To further guide and standardize the application of LMWH in the prevention and treatment of natural abortion, this consensus, including the indications, dosage, treatment course, and monitoring of natural abortion in LMWH, was made by experts in the fields of obstetrics and gynecology, reproductive medicine, rheumatology and pharmacology. The consensus points out that the indications of LMWH for the prevention and treatment of natural abortion are mainly antiphospholipid syndrome (APS), pre-thromobolic state (PTS), autoimmune disease (AID), etc. According to the condition, LMWH can be used with preventive dosage and therapeutic dosage. Whether LMWH can improve pregnancy outcome in patients with unexplained recurrent spontaneous abortion (URSA), repeated biochemical pregnancy (RBP), and repeated planting failure (RPF) is unproven, and there is no enough clinical evidence to show that LMWH can increase the level of blood β-human chorionic gonadotrophin (hCG). LMWH can be applied to patients with recurrent spontaneous abortion (RSA) who also have a long course of hypertension, diabetes, chronic kidney diseases and may have vascular endothelial injury, but the efficacy remains to be further verified. Clinically, indications range expansion and super-large dosage should be avoided.

Low molecular weight heparins (LMWH); Spontaneous abortion; Prevention and treatment; Consensus